Companion diagnostics are very complex and expensive to develop. Our intention is to collect exploratory data to determine if bisantrene specifically effects m6A levels in patients in an exploratory add-on to the cardioprotection study, and only if it does, then start the process of developing a companion diagnostic. This is the most capital efficient approach.
We have done a lot of work identifying what approaches we could use to develop a practical diagnostic. The good news
Companion diagnostics are very complex and expensive to develop....
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.48 |
Change
-0.040(2.63%) |
Mkt cap ! $252.5M | |||
| Open | High | Low | Value | Volume |
| $1.55 | $1.57 | $1.47 | $144.1K | 95.09K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 280 | $1.48 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 300 | 1 |
View Market Depth
| Last trade - 14.50pm 22/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.49 |
Change
-0.040 ( 1.66 %) |
||||
| Open | High | Low | Volume | ||
| $1.53 | $1.56 | $1.47 | 9727 | ||
| Last updated 15.04pm 22/05/2024 ? | |||||
| RAC (ASX) Chart |